Peter Heerma Sells 8,282 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) EVP Peter Heerma sold 8,282 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $65.07, for a total value of $538,909.74. Following the completion of the sale, the executive vice president directly owned 117,066 shares of the company’s stock, valued at approximately $7,617,484.62. This represents a 6.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Peter Heerma also recently made the following trade(s):

• On Tuesday, September 15th, Peter Heerma sold 102,190 shares of Travere Therapeutics stock. The stock was sold at an average price of $62.26, for a total value of $6,362,349.40.
• On Wednesday, September 16th, Peter Heerma sold 172,717 shares of Travere Therapeutics stock. The stock was sold at an average price of $63.43, for a total value of $10,955,439.31.

Travere Therapeutics Stock Down 3.1%

Shares of NASDAQ:TVTX opened at $62.76 on Friday. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58. The business has a fifty day moving average of $61.76 and a two-hundred day moving average of $48.60. The stock has a market cap of $5.92 billion, a P/E ratio of -136.43 and a beta of 1.05. Travere Therapeutics, Inc. has a 52-week low of $22.06 and a 52-week high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03. The business had revenue of $169.58 million for the quarter, compared to analyst estimates of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The company’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 EPS. On average, research analysts expect that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent analyst reports. Evercore set a $78.00 target price on shares of Travere Therapeutics in a report on Monday, August 10th. Wells Fargo & Company lifted their price target on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research report on Friday, June 12th. Canaccord Genuity Group upped their price objective on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings lowered Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Finally, TD Cowen raised their target price on Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $68.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. S&CO Inc. purchased a new position in Travere Therapeutics during the 2nd quarter valued at about $3,181,000. Artia Global Partners LP acquired a new position in Travere Therapeutics in the 2nd quarter valued at about $19,260,000. Profund Advisors LLC increased its stake in Travere Therapeutics by 209.3% during the fourth quarter. Profund Advisors LLC now owns 62,604 shares of the company’s stock worth $2,392,000 after purchasing an additional 42,366 shares during the period. Quantinno Capital Management LP increased its stake in Travere Therapeutics by 354.4% during the first quarter. Quantinno Capital Management LP now owns 68,317 shares of the company’s stock worth $2,030,000 after purchasing an additional 53,283 shares during the period. Finally, Elmind Capital LP acquired a new stake in shares of Travere Therapeutics during the second quarter worth about $16,622,606.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts maintain a generally favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $68. Several firms have raised their targets to $70-$78, suggesting potential upside from recent trading levels. Travere Therapeutics analyst coverage
• Positive Sentiment: Institutional interest has increased, including new positions from Jupiter Topco and Bank of America, while Wellington Management and Perceptive Advisors expanded their holdings. The buying may reinforce confidence in Travere’s commercial prospects and rare-disease pipeline.
• Neutral Sentiment: Travere will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on FILSPARI and the company’s pipeline, although no new business information was announced. Travere presentation announcement
• Negative Sentiment: Multiple executives and insiders reported selling shares, including CEO Eric Dube, CFO Christopher Cline, CAO Sandra Calvin and several executive vice presidents. Collectively, the disclosed transactions represented roughly $61 million of stock sales, with individual holdings falling by approximately 6% to 60%. The trades were conducted under pre-arranged Rule 10b5-1 plans, which lessens their signaling value, but the concentration of selling may still weigh on investor sentiment and near-term momentum.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.